Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)

Background: Improving outcomes for patients with human epidermal growth factor 2-positive (HER2+) central nervous system (CNS) metastases remains an unmet clinical need. This trial evaluated a novel combination of everolimus, lapatinib and capecitabine for this disease. Methods: Patients with trastu...

Full description

Bibliographic Details
Main Authors: Sara Hurvitz, Rashi Singh, Brad Adams, Julie A. Taguchi, David Chan, Robert A. Dichmann, Aurelio Castrellon, Eddie Hu, Jonathan Berkowitz, Aruna Mani, Brian DiCarlo, Rena Callahan, Ira Smalberg, Xiaoyan Wang, Ivana Meglar, Diego Martinez, Evthokia Hobbs, Dennis J. Slamon
Format: Article
Language:English
Published: SAGE Publishing 2018-11-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835918807339

Similar Items

Similar Items